ALLR NASDAQ
Boston, MA 02139
US
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Jensen Thomas | A-Award | 200,000 | — | 2026-01-28 |
| McLaughlin Gerald W. | A-Award | 45,000 | — | 2026-01-28 |
| Graff Jeremy R. | A-Award | 133,333 | — | 2026-01-28 |
| Ervin Jeffrey S | A-Award | 150,000 | — | 2026-01-28 |
| Hoeiland Jesper | A-Award | 25,000 | — | 2026-01-07 |